Invivyd (IVVD) Gains from Investment Securities (2020 - 2025)
Invivyd posted quarterly Gains from Investment Securities of -$23000.0 for Q4 2025, up 99.67% year-on-year from -$11519.3 in Q4 2024, and down 123.0% on a QoQ basis from $100000.0 in Q2 2025.
Invivyd (IVVD) has 6 years of Gains from Investment Securities data on file, last reported at -$23000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 99.67% year-over-year to -$23000.0; the trailing twelve-month figure through Dec 2025 stood at $177000.0 (up 102.69% YoY), and the FY2025 full-year result was $2.1 million, down 85.99% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$23000.0, down from $100000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $17.5 million in Q3 2021 and bottomed at -$6.9 million in Q4 2024.
- The 5-year median for Gains from Investment Securities is $100000.0 (2023), against an average of $1.9 million.
- The widest annual swing landed in 2023, when Gains from Investment Securities surged 200.16%; it then sank 57208.33% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$6.0 million in 2021, then jumped by 31.75% to -$4.1 million in 2022, then jumped by 99.71% to -$12000.0 in 2023, then tumbled by 57208.33% to -$6.9 million in 2024, then surged by 99.67% to -$23000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$23000.0 (Q4 2025), $100000.0 (Q2 2025), and $100000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,000.00 |
| Dec 31, 2025 | -23,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | -6.88 Mn |
| Dec 31, 2024 | -6.88 Mn |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 3.65 Mn |
| Mar 31, 2024 | 3.65 Mn |
| Dec 31, 2023 | -12,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 3.06 Mn |
| Mar 31, 2023 | 3.06 Mn |
| Dec 31, 2022 | -4.11 Mn |
| Dec 31, 2022 | -4.11 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | -3.06 Mn |
| Mar 31, 2022 | -3.06 Mn |
| Dec 31, 2021 | -6.02 Mn |
| Dec 31, 2021 | -6.02 Mn |
| Sep 30, 2021 | 17.46 Mn |
| Sep 30, 2021 | 17.46 Mn |
| Jun 30, 2021 | 14.93 Mn |
| Jun 30, 2021 | 14.93 Mn |
| Dec 31, 2020 | 2.97 Mn |
| Dec 31, 2020 | 2.97 Mn |